Todos Medical Announces Insolvency Proceedings in Israel
InvestmentManagement ChangesCustomers
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
PartnersInvestmentExpand
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
Partners
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
Investment
Todos Medical's Letter of Intent with Provista Diagnostics set to license sepsis diagnostic testing
Partners
Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics
Todos Medical Begins Trading on the OTC Pink Marketplace
Todos Medical Supports Long COVID Awareness Day
Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
InvestmentPartners
Todos Medical releases corporate update around validation plan for PCR-based Avian Influenza testing
Investment
Todos Medical Provides Corporate Update
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics
Todos Medical to Present at the RHK 2022 Disruptive Growth Conference
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
CustomersExpand
Todos Medical to Attend World Antiviral Congress
Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
Todos Medical Announces Third Quarter 2022 Financial Results
Todos Medical to Host Third Quarter 2022 Earnings and Business Update Conference Call on November 15, 2022
Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A.
Todos Medical Announces BioFuture™ NYC 2022 Presentation
+ 32 more articles